A Systematic Overview of Chemotherapy Effects in Non-Small Cell Lung Cancer

References

• Wersall JP, Barlow L, Eklund G. A decline in the lung cancer incidence amongst men in Swedish cities. Acta Oncol 1996; 35: 395-7. (01)
   Google Scholar
• Mountain CF. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710–7. (L1/5 319)
   Google Scholar
• Vrdoljak E, Mise K, Sapunar D, et al. Survival analysis of untreated patients with non-small-cell lung cancer. Chest 1994; 106: 1797-800. (R1/130)
   Google Scholar
• Malmberg R, Bergman B, Branehog I, et al. Lung cancer in West Sweden 1976-1985. Acta Oncol 1996; 35: 185–92. (R1/3 285)
   PubMed Web of Science ®Google Scholar
• Non-small Cell Lung Cancer Collaborative Group. Chemother-apy in non-small cell lung cancer. A meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311: 899–909. (M1/9 387)
   Google Scholar
• Berino F, Sant M, Verdecchia A, et al. Survival of cancer patients in Europe. Lyon: WHO. IARC Scientific Publications, 1995; 132. (R1/167 068)
   Google Scholar
• Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. J Clin Oncol 1997; 15: 2996–3018. (L1)
   Google Scholar
• Bonomi PD, Finkelstein DM, Ruck-deschd JC, et al. Combi-nation chemotherapy vs single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: A study of the Eastern Cooperative Oncology Group. J Clin Oncol 1989; 7: 1602-13. (C1/743)
   Google Scholar
• PORT Meta-analysis Trialists Group. Postoperative radiother-apy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998; 352: 257–63. (M1/2 128)
   Google Scholar
• Marino P, Pampallona S, Preatoni A, et al. Chemotherapy vs supportive care in advanced non-small cell lung cancer. Results of a meta-analysis of the literature. Chest 1994; 106: 861-5. (M2/712)
   Google Scholar
• Souquet PJ, Chauvin F, Boissel JP, et al. Polychemotherapy in advanced non-small cell lung cancer: a meta-analysis. Lancet 1993; 342: 19-21. (M2/706)
   Google Scholar
• Marino P, Preatoni A, Cantoni A, et al. Single-agent chemother-apy vs combination chemotherapy in advanced non-small cell lung cancer: A quality and meta-analysis study. Lung Cancer 1995; 13: 1–12. (M2/1 493)
   PubMed Web of Science ®Google Scholar
• Le Chevalier T, Brisgand D, Douillard JY, et al. Randomized study of vinorelbine and cisplatin vs vindesine and cisplatin vs vinorelbine alone in advanced non-small-cell lung cancer: results of a European multicentre trial including 612 patients. J Clin Oncol 1994; 12: 360-7. (C1/612)
   Google Scholar
• Elliott JA, Ahmedzai S, Hole D. Vindesine and cisplatin combination chemotherapy compared with vindesine as a single agent in the management of non-small cell lung cancer: a randomized study. Eur J Cancer Clin Oncol 1984; 20: 1025-32. (C1/105)
   Google Scholar
• Helsing M, Bergman B, Thaning L, et al. Quality of life and survival in patients with advanced non-small cell lung cancer receiving supportive care plus chemotherapy with carboplatin and etoposide or supportive care only. A multicentre ran-domised phase III trial. For the Joint Lung Cancer Study Group. Eur J Cancer 1998; 34: 1036–44. (C2/48, P1/102)
   Google Scholar
• Klastersky J, Sculier JP, Lacroix H, et al. A randomized study comparing cisplatin or carboplain with etoposide in patients with advanced non-small-cell lung cancer: European Organiza-tion for Research and Treatment of Cancer Protocol 07861. For the European Organization for Research and Treatment of Cancer Lung Cancer Working Party. J Clin Oncol 1990; 8: 1556-62. (C1/109)
   Google Scholar
• Jeremic B, Shibamoto Y, Acimovic L, et al. Prolonged admin-istration of oral etoposide alone or with intravenous carbo-platin in stage IV non-small cell lung cancer: A randomized trial. Lung Cancer 1997; 18: 179-88. (C1/120)
   Google Scholar
• Hollen PJ, Gralla RJ, Cox C, et al. A dilemma in analysis: issues in the serial measurement of quality of life in patients with advanced lung cancer. Lung Cancer 1997; 18: 119-36. (R1/673)
   Google Scholar
• Thongprasert S, Sanguanmitra P. Usefulness of the Thai modified functional living index-cancer (T-FLIC) and the Thai modified quality of life index (T-QLI) for advanced non-small cell lung cancer. Jap J Cancer Chemother 1995; 22 (Suppl. 3): 226–9. (C2/288)
   Google Scholar
• Thongprasert S, Sanguanmitra P, Juthapan W. Final report on quality of life and clinical outcomes in advanced non-small cell lung cancer. Proc Am Soc Clin Oncol 1996; 15: 407. (C2/288)
   Google Scholar
• Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17: 3188-94. (C1/797)
   Google Scholar
• The Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91: 66-72. (C1/161)
   Google Scholar
• Shepherd FA. Single agent gemcitabine activity in non-small cell lung cancer. Lung Cancer 1997; 18 (2): 114. (L2/501)
   Google Scholar
• Anderson H, Hopwood P, Stephens RJ, et al. Gemcitabine plus best supportive care (BSC) vs BSC in inoperable non-small cell lung cancer - A randomized trial with quality of life as the primary outcome. Br J Cancer 2000; 83: 447-53. (C1/299)
   Google Scholar
• Manegold C, Drings P, von Pawel J, et al. Single-agent gemcitabine vs cisplatin-etoposide: early results of a ran-domised phase II study in locally advanced or metastatic non-small cell lung cancer. Ann Oncol 1997; 8: 525-9. (C2/ 147)
   Google Scholar
• Cardenal F, Lopez-Cabrerizo MP, Ant6n A, et al. Random-ized phase III study of gemcitabine-cisplatin vs etoposide-cis-platin in the treatment of locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 1999; 17: 12-8. (C1/135)
   Google Scholar
• Sandler AB, Nemunaitis J, Denham C, et al. Phase III trial of gemcitabine plus cisplatin vs cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 2000; 18: 122-30. (C2/522)
   Google Scholar
• Cerny T, Calderoni A. Phase II results of taxanes in lung cancer. In: Johnson DH, Klastersky J, eds. Taxanes in lung cancer therapy. New York: Marcel Dekker, 1998: 39–56. (L1)
   Google Scholar
• Giaccone G, Splinter TA, Debruyne C, et al. Randomized study of paclitaxel-cisplatin vs cisplatin-teniposide in patients with advanced non-small-cell lung cancer. For the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1998; 16: 2133-41. (C1/332)
   Google Scholar
• Johnson DH. Recent advances in the treatment of non-small cell lung cancer with chemotherapy: The ECOG experience. Lung Cancer 1997; 18 (Suppl. 2): 146–7. (C1/574)
   Google Scholar
• Bonomi P, Kim C, Kugler K, et al. Results of a phase III trial comparing taxol-cisplatin (TC) regimens to etoposide-cisplatin (EC) in non-small cell lung cancer (NSCLC). Lung Cancer 1997; 18 (Suppl. 1): 10 Abstr. (C3/574)
   Google Scholar
• Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care vs supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000; 92: 1074-80. (C1/157)
   Google Scholar
• Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicen-tre, randomized, phase III study of docetaxel plus best support-ive care vs best supportive care in chemotherapy-naive patients with metastatic non-resectable localized non-small cell lung cancer. Lung Cancer 2000; 27: 145-7. (C1/207)
   Google Scholar
• Fukuoka M, Niitani H, Suzuki A, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small cell lung cancer. For the CPT-11 Lung Cancer Study Group. J Clin Oncol 1992; 10: 16–20. (P1/73)
   PubMed Web of Science ®Google Scholar
• Perez-Soler R, Fossella FV, Glisson BS, et al. Phase II study of topotecan in patients with advanced non-small-cell lung cancer previously untreated with chemotherapy. J Clin Oncol 1996; 14: 503–13. (P1/40)
   Google Scholar
• Lynch TJ Jr, Kalish L, Strauss G, et al. Phase II study of topotecan in metastatic non-small-cell lung cancer. J Clin Oncol 1994; 12: 347-52. (P2/20)
   Google Scholar
• Fukuoka M, Nagao K, Ohashi Y, et al. Impact of irinotecan and cisplatinon survival in previously untreated metastatic non-small cell lung cancer. Proc Am Soc Clin Oncol 2000; 19 Abstr: 495. (C3/358)
   Google Scholar
• Depierre A, Lemarie E, Dabouis G. A phase II study of Navelbine (Vinorelbine) in the treatment of non-small cell lung cancer. Am J Clin Oncol 1991; 14: 115-9. (P1/78)
   Google Scholar
• Crawford J, O'Rourke M, Schiller JH, et al. Randomized trial of vinorelbine compared with fluorouracil plus leucovorin in patients with stage IV non-small-cell lung cancer. J Clin Oncol 1996; 14: 2774-84. (C1/216)
   Google Scholar
• Wozniak AJ, Crowley JJ, Balcerzak SP, et al. Randomized trial comparing cisplatin with cisplatin plus vinorelbine in the treatment of advanced non-small-cell lung cancer: A Southwest Oncology Group study. J Clin Oncol 1998; 16: 2459-65. (C1/432)
   Google Scholar
• Fossella FV, DeVore R, Kerr R, et al. Phase III trial of docetaxel 100 mg/m2 or 75 mg/m2 vs vinorelbine/ifosfamide for non-small cell lung cancer previously treated with platinum-based chemotherapy. Proc Am Soc Clin Oncol 1999; 18 Abstr: 460. (C3/373)
   Google Scholar
• Shepherd FA, Dancey J, Ramlau R, et al. Prospective random-ized trial of docetaxel vs best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18: 2095–103. (Cl 204)
   PubMed Web of Science ®Google Scholar
• Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone vs combined chemotherapy and radio-therapy in stage Ma and Mb non-small cell lung cancer. A meta-analysis. Cancer 1995; 76: 593-601. (M2/1887)
   Google Scholar
• Le Chevalier T, Arriagada R, Quoix E, et al. Radiotherapy alone vs combined chemotherapy and radiotherapy in nonre-sectable non-small-cell lung cancer. J Natl Cancer Inst 1991; 83: 417-23. (C1/353)
   Google Scholar
• Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Effects of concomitant cisplatin and radiotherapy on inopera-ble non-small cell lung cancer. N Engl J Med 1992; 326: 524–30. (C1/331)
   Google Scholar
• Trovo MG, Minatel E, Franchin G, et al. Radiotherapy vs radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int .1- Radiat Oncol Biol Phys 1992; 24: 11–5. (C2/173)
   PubMed Web of Science ®Google Scholar
• Jeremic B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: A randomized study. J Clin Oncol 1996; 14: 1065-70. (C1/131)
   Google Scholar
• Jeremic B, Shibamoto Y, Acimovic L, et al. Randomized trial of hyperfractionated radiation therapy with or without concur-rent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 1995; 13: 452-8. (C1/169)
   Google Scholar
• Clamon G, Herndon J, Cooper R, et al. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer. A phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999; 1: 4-11. (C1/283)
   Google Scholar
• Pass HI, Pogrebniak HW, Steinberg SM, et al. Randomized trial of neoadjuvant therapy for lung cancer: interim analysis. Ann Oncol 1992; 3: 127-30. (C3/27)
   Google Scholar
• Rosell R, Gomez-Codina J, Camps C, et al. A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. N Engl J Med 1994; 330: 153-8. (C2/60)
   Google Scholar
• Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86: 673-80. (C2/60)
   Google Scholar
• Westeel V, Chevret S, Milleron B, et al. Phase III trial of perioperative chemotherapy in resectable stage I (except T1N0), II, Ma non-small cell lung cancer: the French experi-ence. The First Int Symp on Malignancies of the Chest and Neck. Lung Cancer 1999; 25: 239-40. (C2/373)
   Google Scholar